SCHEMBL20117205

SCHEMBL20117205

COC(=O)C1CCN(C(=O)[C@H]2CC(=O)N(c3ccccc3)C2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.65
TSHR P16473 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
MAPK1 P28482 2/20 0.58
MAPT P10636 1/20 0.58
PKM P14618 1/20 0.58
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
RXFP1 Q9HBX9 1/20 0.53
ALDH1A1 P00352 3/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA4 P22748 1/20 0.53
CA6 P23280 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
CA13 Q8N1Q1 1/20 0.53
CA14 Q9ULX7 1/20 0.53
CA5B Q9Y2D0 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116514 1.00 NPC1 (0.65) NPC1TSHRSMN1; SMN2MAPK1MAPT
SCHEMBL20116499 0.86 SMN1; SMN2 (0.65) NPC1TSHRSMN1; SMN2MAPK1MAPT
SCHEMBL20116263 0.86 SMN1; SMN2 (0.65) NPC1TSHRSMN1; SMN2MAPK1MAPT
SCHEMBL20116636 0.86 SMN1; SMN2 (0.65) NPC1TSHRSMN1; SMN2MAPK1MAPT
SCHEMBL892079 0.86 ALDH1A1 (0.67) NPC1TSHRSMN1; SMN2MAPTMEN1
SCHEMBL20116446 0.84 KMT2A (0.57) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL30506338 0.84 KMT2A (0.57) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL8305710 0.83 ALDH1A1 (0.51) NPC1TSHRSMN1; SMN2MAPTALDH1A1
SCHEMBL28309453 0.81 RXFP1 (0.73) NPC1TSHRSMN1; SMN2MAPK1MAPT
SCHEMBL28309449 0.81 RXFP1 (0.73) NPC1TSHRSMN1; SMN2MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 CN disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
CN-110099898-B Compounds and uses thereof 优曼尼蒂治疗公司 2023-07-25 CN disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 NPC1 72/4885TSHR 4679/4885SMN1; SMN2 13/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 NPC1 72/4885TSHR 4679/4885SMN1; SMN2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.